Aptevo Therapeutics Files 8-K: Material Agreement
Ticker: APVO · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-K
Related Tickers: APVO
TL;DR
APVO signed a material definitive agreement, filing an 8-K today.
AI Summary
On June 18, 2025, Aptevo Therapeutics Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.
Why It Matters
This filing indicates a significant new agreement for Aptevo Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the nature of which is not yet detailed.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- June 18, 2025 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement entered into by Aptevo Therapeutics?
The provided excerpt does not specify the details of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 18, 2025.
What is Aptevo Therapeutics Inc.'s principal executive office address?
The principal executive offices are located at 2401 4th Avenue Suite 1050, Seattle, Washington, 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number is 001-37746.
What is the Standard Industrial Classification code for Aptevo Therapeutics Inc.?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Aptevo Therapeutics Inc. (APVO).